STLN SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Nov 5, 2026

8-K

Brad Hively to Depart Starling Oncology Board of Directors

Sep 1, 2026

8-K

Starling Oncology, Inc. Enters into $25 Million Revolving Credit Facility

Aug 21, 2026

8-K

Form 8-K - Current report - Item 2.02 Item 9.01

Aug 6, 2026

8-K

The Oncology Institute Rebrands to Starling Oncology and Updates Ticker Symbol

Aug 3, 2026

8-K

The Oncology Institute Completes Strategic Refinancing with OrbiMed

Jul 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

August 2025 ATM

Aug 13, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 1,227,161

Feb 10, 2023

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 87,829,226 | Warrants amount: 6,327,542

Feb 10, 2023

424B3

UPDATED

Jan 9, 2023

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 20,459,040 | Conversion price: $8.57 | Offering amount: $110,000,000.00

Dec 1, 2022

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 1,342,076

Dec 1, 2022

Registrations

TYPE

HEADLINE

FILED AT

S-3/A

OFFERING (Shelf/At-the-Market Offering) - BTIG, LLC

Jun 16, 2025

S-3

June 2025 SHELF

Jun 6, 2025

S-3

SHARE RESALE REGISTRATION | Shares amount: 27,924,611 | Warrants amount: 22,114,918

May 9, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

Apr 8, 2025

POS AM

Form POS AM - Post-Effective amendments for registration statement

Jan 27, 2023

POS AM

Form POS AM - Post-Effective amendments for registration statement

Jan 27, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 27, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 27, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 14, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 2, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Hively Brad (Reporting)

Aug 24, 2026

144

Form 144 - Report of proposed sale of securities

Aug 21, 2026

Chernett Jorey (Reporting)

Aug 17, 2026

Kaushal Mohit (Reporting)

Jul 29, 2026

McGeorge Anne (Reporting)

Jul 29, 2026

Pacala Mark L (Reporting)

Jul 29, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 20, 2025

CORRESP

Form CORRESP - Correspondence

Jun 16, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jun 12, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

May 19, 2025

CORRESP

Form CORRESP - Correspondence

May 14, 2025

LETTER

Form UPLOAD - SEC-generated letter

May 14, 2025

Starling Oncology, Inc. STLN · SEC Filings